^
Association details:
| Biomarker: | BRCA2 deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD04-01: Evaluation of copy number and allelic imbalance of BRCA2 by next-generation sequencing to predict prognosis and drug sensitivity in prostate cancer
Published date:
03/31/2023
Excerpt:
...patients with decreased BRCA2 CN were presumed to have somatic heterozygous or homozygous deletions….In the mCRPC study, 8 of 18 patients with BRCA2 alterations have shown to have BRCA2 deletions. Of the 8 patients, 4 patients with BRCA2 CN less than 0.8 had an OR to the PARP inhibitor olaparib, while the other 4 patients with BRCA2 CN greater than 0.8 did not have an OR to olaparib.
Source:
Title:
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Published date:
05/27/2021
Excerpt:
BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion...Overall, APCs with homozygous BRCA2 deletion are exceptional responders...
DOI:
10.1158/2159-8290.CD-21-0007
Source:
Title:
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Excerpt:
Of these 16 patients, 14 (88%) had a response to olaparib, including all 7 patients with BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations) and 4 of 5 with ATM aberrations.
DOI:
10.1056/NEJMoa1506859
Trial ID:
